Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy

Daniel J. Landsburg, Emily C. Ayers, David A. Bond, Kami J. Maddocks, Reem Karmali, Amir Behdad, Madeira Curry, Nina D. Wagner-Johnston, Dipenkumar Modi, Radhakrishnan Ramchandren, Sarit E. Assouline, Rawan Faramand, Julio C. Chavez, Pallawi Torka, Angel Mier Hicks, L. Jeffrey Medeiros, Shaoying Li

Research output: Contribution to journalArticlepeer-review

Abstract

While patients with double-hit lymphoma (DHL) are now frequently treated with intensive front-line immunochemotherapy, outcomes for those who fail these regimens and subsequently receive curative-intent second-line immunochemotherapy are unknown. We identified 55 such patients who achieved an overall/complete response rate of 29%/11%, median progression-free/overall survival (PFS/OS) of 2/5·1 months and one-year PFS/OS of 10/19% following the start of second-line therapy. These outcomes may serve as a standard against which future second-line treatment strategies for relapsed/refractory DHL can be measured and justify investigation of non-cytotoxic therapies in the second-line setting for these patients.

Original languageEnglish (US)
Pages (from-to)313-317
Number of pages5
JournalBritish journal of haematology
Volume189
Issue number2
DOIs
StatePublished - Apr 1 2020

Keywords

  • chemotherapy
  • fluorescence in situ hybridization
  • molecular diagnosis
  • non-Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy'. Together they form a unique fingerprint.

Cite this